Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.
Epistemonikos ID: 8fd8a55ea735f35799e503aa2016cc34611bbeea
First added on: May 10, 2024